Evercore ISI analyst Mark Mahaney initiated coverage of Hims & Hers with an In Line rating and $33 price target Given an investment cycle spanning through 2026, the firm views the current valuation as “reasonable,” with some multiple risk given a near-term outlook for material revenue and subscriber growth deceleration and flattish EBITDA margins, the analyst tells investors. However, the firm also believes the market may be underappreciating the durability and diversity of Hims’ core platform, the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- HIMS Stock Falls after BofA Slashes Price Target to a Street-Low of $29
- Hims & Hers price target lowered to $29 from $32 at BofA
- Hims & Hers again left off Novo partner list, says Citi
- Mixed options sentiment in Hims and Hers Health with shares down 2.47%